An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers
{{output}}
Background: CD3-based bispecific T cell engagers (bsTCEs) are one of the most promising bispecific antibodies for effective cancer treatments. To elicit target-specific T cell-mediated cytotoxicity, these bsTCEs contain at least ... ...
